390406-08-3

Usage

Uses

Used in Pharmaceutical Industry:
Benzenemethanol,-(aminomethyl)-3,4-dichloro-, (S)is used as a chiral auxiliary in the pharmaceutical industry for the synthesis of enantiomerically pure compounds. Its ability to control the stereochemistry of chemical reactions ensures the production of the desired enantiomer, which is crucial for the biological activity and safety of the final drug product.
Used in Organic Synthesis:
In the field of organic synthesis, Benzenemethanol,-(aminomethyl)-3,4-dichloro-, (S)is used as a reagent to facilitate the synthesis of various biologically active compounds. Its presence in the reaction can help achieve higher yields and selectivity, leading to more efficient and cost-effective synthetic routes.
Used as an Intermediate in Chemical Production:
Benzenemethanol,-(aminomethyl)-3,4-dichloro-, (S)also serves as an intermediate in the production of other chemicals. Its unique structural features and reactivity make it a valuable building block for the synthesis of a wide range of chemical products, including agrochemicals, fragrances, and specialty chemicals.

Upstream product

• 380650-10-2 2-amino-1-(3,4-dichloro-phenyl)-ethanone 
• 41995-19-1 2-amino-1-(3,4-dichloro-phenyl)-ethanone; hydrochloride 
• 6287-38-3 3,4-dichlorobenzaldehyde 
• 357952-85-3 (S)-(+)-1-(3,4-Dichlorophenyl)-2-(p-tolylsulfonyloxy)ethanol 
• 473552-24-8 (R)-(-)-2-azido-1-(3',4'-dichlorophenyl)ethanol 
• 42981-08-8 2,3',4'-trichloroacetophenone 
• 53065-95-5 2-chloro-1-(3,4-dichlorophenyl)ethan-1-ol 
• 2632-10-2 2-bromo-1-(3,4-dichlorophenyl)ethanone 
• 2642-63-9 3',4'-dichloroacetophenone 
• 95-50-1 1,2-dichloro-benzene 
• 958452-69-2 (3,4-dichloro-phenyl)-glyoxal-2-oxime 

Downstream Products

• 1254942-00-1 5-([1,2,4]triazolo[1,5-α]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline 
• 1254941-99-5 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline 

Relevant academic research and scientific papers

Minor enantiomer recycling: Application to enantioselective syntheses of beta blockers

Continuous recycling of the minor product enantiomer obtained from the acetylcyanation of prochiral aldehydes provided access to highly enantiomerically enriched products. Cyanohydrin derivatives, which under normal conditions are obtained with modest or poor enantiomeric ratios, were formed with high enantiomeric purity by using a reinforcing combination of a chiral Lewis acid catalyst and a biocatalyst. The primarily obtained products were transformed into β-adrenergic antagonists (S)-propanolol, (R)-dichloroisoproterenol, and (R)-pronethalol by means of a two-step procedure.

ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF

Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.

ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase

A novel class of 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase is described. This report discusses the SAR of 4-(2-hydroxy-2-phenylethylamino)-substituted pyridones with improved IGF-1R potency.

Indole, indazole and indoline derivatives as CETP inhibitors

The present invention relates to compounds of formula (I): wherein —X—Y—, R1 to R11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.

Application of optically active 1,2-diol monotosylates for synthesis of β-azido and β-amino alcohols with very high enantiomeric purity. Synthesis of enantiopure (R)-octopamine, (R)-tembamide and (R)-aegeline

A very convenient and highly efficient synthesis of near enantiopure β-azido and β-amino alcohols including biologically active substances such as (R)-octopamine, (R)-tembamide and (R)-aegeline from optically active 1,2-diol monotosylates is reported.